Angitia gets $130M Series D for pipeline of musculoskeletal drugs
Angitia 生物医药获1.3亿美元D轮融资，用于推进肌肉骨骼系统药物管线

A US-China biotech has reeled in $130 million for three biologics in clinical testing for musculoskeletal diseases, including one in which Ultragenyx recently came up short.
一家美中生物科技公司为三款用于肌肉骨骼疾病、处于临床试验阶段的生物制剂募集了1.3亿美元资金，其中一款是Ultragenyx近期未达预期的项目。